Dimerix

Dimerix Licenses DMX-200 to Everest Medicine in ~$340M Deal, Targeting Asia's FSGS Market

Dimerix has licensed DMX-200 for FSGS to Everest Medicine in Greater China, South Korea, and Southeast Asia, a deal valued at ~$340M plus tiered royalties. This partnership offloads regional regulatory and commercialization burdens from Dimerix, leveraging Everest's local market expertise. For procurement and regulatory leaders, this signals accelerated market entry for DMX-200 in key Asian markets, impacting future supply chain planning and regional regulatory strategies.